Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Celularity Inc. Class A Common Stock

CELU

Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.

Last trade $0.5826
Day change -$0.0365 (-5.90%)
Day range $0.555 – $0.677
Volume 214,649
Market cap $20M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$20.12M
Price / earnings
—
Price / book
-0.57×
Price / sales
1.08×
EV / sales
3.06×
EV / EBITDA
-1.34×

Profitability

Earnings per share
-$1.43
Return on assets
-48.15%
Return on equity
130.31%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-1.06×
Current ratio
0.11×
Quick ratio
0.1×
Cash ratio
0.01×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.92M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CELU, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$5.43M$3.85M$4.1M$5.28M$5.74M$11.43M$18.13M$9.3M
Cost of revenue$2.35M$1.45M$7.37M$3.9M$5.24M$3.55M$7.34M$3.88M
Gross profit$3.09M$2.39M-$3.27M$1.38M$494K$7.87M$10.79M$5.41M
Selling, general and administrative$4.94M$9.17M$15.06M$9.31M$12.63M$14.26M$16.06M$12.65M
Research and development$2.03M$2.99M$3.35M$4.6M$3.35M$3.73M$3.83M$3.92M
Total operating expenses$7.32M$12.53M$18.79M$14.28M$16.36M$18.36M$20.07M$16.94M
Operating income-$4.24M-$10.13M-$22.06M-$12.9M-$15.86M-$10.49M-$9.28M-$11.53M
Interest expense-$177K-$352K-$897K-$1.48M-$1.94M-$2.44M-$1.81M-$1.75M
Income before taxes$706K$675K-$24.36M-$23.08M-$24.52M-$19.75M-$13.29M-$16.1M
Income taxes$0$0$3K$0$0$0$0$0
Net income$706K$675K-$24.36M-$23.08M-$24.52M-$19.75M-$13.29M-$16.1M
Net income attributable to common shareholders$546K$675K-$24.45M-$23.08M-$24.52M-$19.82M-$13.29M-$16.1M
EBITDA-$2.7M-$8.54M-$20.2M-$11.13M-$14.03M-$8.65M-$7.6M-$9.63M
Basic earnings per share$0.02$0.02-$0.86-$0.88-$1.02-$0.84-$0.60-$0.73
Diluted earnings per share$0.02$0.02-$0.86-$0.88-$1.02-$0.84-$0.60-$0.73

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Celularity Provides Update Regarding Nasdaq Listing Compliance

Celularity Inc. (Nasdaq: CELU) received a notification from Nasdaq on August 21, 2026, stating the company is not in compliance with listing rules due to failure to timely file its Quarterly Reports on Form 10-Q for periods ended June 30, 2026 and March 31, 2026. The company has until September 4, 2026 to submit a compliance plan, with a maximum 180-day grace period until November 16, 2026. Trading of the stock continues unaffected while the company works to complete and file the delayed reports.

GlobeNewswire Inc.

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Inc. received a notification from Nasdaq on May 27, 2026, indicating non-compliance with Listing Rule 5250(c)(1) due to delayed filing of its Quarterly Report on Form 10-Q for Q1 2026. The company has until July 28, 2026, to submit a compliance plan, with a potential extension until November 16, 2026. Trading of the stock continues unaffected, and the company is working to file the report and regain compliance.

Benzinga

EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue

NexGel (NASDAQ: NXGL) agreed to acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity (NASDAQ: CELU). The transaction is expected to nearly triple NexGel's annual revenue to approximately $35 million in 2026 and make the company immediately profitable. The portfolio includes six commercial-stage products focused on tendon repair, skin grafts, and bone growth with over a decade of clinical use and existing insurance reimbursement pathways.

GlobeNewswire Inc.

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity received a Nasdaq notification for not timely filing its Quarterly Report on Form 10-Q for June 30, 2025, potentially risking its listing compliance, with a deadline of September 5, 2025 to submit a compliance plan.

GlobeNewswire Inc.

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Inc. (CELU) announced that it did not timely file its Q1 2025 financial report, leading to a Nasdaq non-compliance notice. The company has 60 days to submit a plan to regain compliance and may be granted an extension until November 2025 if the plan is accepted.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 29, 20241-for-10reverse split